» Articles » PMID: 36131041

Compartment-specific Mutational Landscape of Clonal Hematopoiesis

Abstract

Clonal hematopoiesis (CH) is characterized by somatic mutations in blood cells of individuals without hematologic disease. While the mutational landscape of CH in peripheral blood (PB) has been well characterized, detailed analyses addressing its spatial and cellular distribution in the bone marrow (BM) compartment are sparse. We studied CH driver mutations in healthy individuals (n = 261) across different anatomical and cellular compartments. Variant allele frequencies were higher in BM than PB and positively correlated with the number of driver variants, yet remained stable during a median of 12 months of follow-up. In CH carriers undergoing simultaneous bilateral hip replacement, we detected ASXL1-mutant clones in one anatomical location but not the contralateral side, indicating intra-patient spatial heterogeneity. Analyses of lineage involvement in ASXL1-mutated CH showed enriched clonality in BM stem and myeloid progenitor cells, while lymphocytes were particularly involved in individuals carrying the c.1934dupG variant, indicating different ASXL1 mutations may have distinct lineage distribution patterns. Patients with overt myeloid malignancies showed higher mutation numbers and allele frequencies and a shifting mutation landscape, notably characterized by increasing prevalence of DNMT3A codon R882 variants. Collectively, our data provide novel insights into the genetics, evolution, and spatial and lineage-specific BM involvement of CH.

Citing Articles

Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche.

Winter S, Gotze K, Hecker J, Metzeler K, Guezguez B, Woods K Leukemia. 2024; 38(5):936-946.

PMID: 38514772 PMC: 11073997. DOI: 10.1038/s41375-024-02226-6.


Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential.

Cacic A, Schulz F, Germing U, Dietrich S, Gattermann N Front Oncol. 2024; 13:1303785.

PMID: 38162500 PMC: 10754976. DOI: 10.3389/fonc.2023.1303785.


Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients.

Panagiota V, Kerschbaum J, Penack O, Stein C, Arends C, Koenecke C Hemasphere. 2023; 7(10):e957.

PMID: 37799345 PMC: 10550045. DOI: 10.1097/HS9.0000000000000957.


Clonal haematopoiesis - a novel entity that modifies pathological processes in elderly.

Belotserkovskaya E, Golotin V, Uyanik B, Demidov O Cell Death Discov. 2023; 9(1):345.

PMID: 37726289 PMC: 10509183. DOI: 10.1038/s41420-023-01590-z.


Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS.

Buck M, Bast L, Hecker J, Riviere J, Rothenberg-Thurley M, Vogel L iScience. 2023; 26(8):107328.

PMID: 37520699 PMC: 10382887. DOI: 10.1016/j.isci.2023.107328.


References
1.
Busque L, Patel J, Figueroa M, Vasanthakumar A, Provost S, Hamilou Z . Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012; 44(11):1179-81. PMC: 3483435. DOI: 10.1038/ng.2413. View

2.
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman P, Mar B . Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-98. PMC: 4306669. DOI: 10.1056/NEJMoa1408617. View

3.
Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

4.
Terao C, Suzuki A, Momozawa Y, Akiyama M, Ishigaki K, Yamamoto K . Chromosomal alterations among age-related haematopoietic clones in Japan. Nature. 2020; 584(7819):130-135. PMC: 7489641. DOI: 10.1038/s41586-020-2426-2. View

5.
Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View